---
title: "BioVie posts corporate presentation outlining bezisterim and BIV201 clinical programs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295103451.md"
description: "BioVie released a corporate presentation detailing its clinical programs for bezisterim and BIV201. Bezisterim, targeting TNFα-driven inflammation, has topline data expected in Q3 2026 for Phase 2b trials in Parkinson’s and Long COVID. BIV201, an IV terlipressin formulation for ascites, is Phase 3-ready with an FDA-agreed trial design. The company cited significant US sales potential estimates across these indications."
datetime: "2026-08-06T11:59:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295103451.md)
  - [en](https://longbridge.com/en/news/295103451.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295103451.md)
---

# BioVie posts corporate presentation outlining bezisterim and BIV201 clinical programs

-   BioVie highlighted bezisterim, an oral, blood-brain barrier-penetrating small molecule targeting TNFα-driven inflammation across Parkinson’s, Long COVID, Alzheimer’s. \* Topline data expected in 3Q 2026 for SUNRISE-PD Phase 2b in Parkinson’s disease, with Long COVID Phase 2 results also slated for 3Q 2026. \* Parkinson’s readouts emphasized EPNIC-15, a composite spanning MDS-UPDRS Parts I-III and PDSS-2 to capture motor and non-motor change. \* BIV201, a continuous IV terlipressin formulation for ascites, positioned as Phase 3-ready with an FDA-agreed single registrational trial design. \* Pipeline materials cited annual US sales potential estimates of $3 billion for Parkinson’s, $10 billion for Long COVID, $30 billion for Alzheimer’s, $1.6 billion for ascites. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md)
- [BIVIW.US](https://longbridge.com/en/quote/BIVIW.US.md)

## Related News & Research

- [BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3](https://longbridge.com/en/news/295701512.md)
- [BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration](https://longbridge.com/en/news/295718009.md)
- [BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease](https://longbridge.com/en/news/295220567.md)
- [Rhelion signs supply license with Toronto’s UHN for psilocybin trial in Parkinson’s depression](https://longbridge.com/en/news/296134949.md)
- [BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s disease](https://longbridge.com/en/news/295101020.md)